immedi versu beta-blockad follow thrombolyt therapi patient acut myocardi infarct result thrombolysi myocardi infarct timi ii-b studi thrombolysi myocardi infarct timi phase II trial patient intraven recombin tissue-typ plasminogen activ rt-pa conserv invas strategi studi effect immedi versu beta-block therapi patient elig beta-block therapi group patient immedi intraven group group immedi intraven group hour rt-pa metoprolol mg interv minut total intraven dose mg mg hour first hour mg hour patient group mg day mg day therapi group primari end point global eject fraction hospit discharg ident group region ventricular function similar group overal differ mortal immedi intraven defer group subgroup low risk death week immedi beta-block therapi contrast death beta-block therapi find secondari end point subgroup suffici recommend clinic use incid reinfarct recurr chest pain day immedi intraven group appropri postinfarct patient beta-block safe thrombolyt therapi decreas myocardi ischemia reinfarct first week benefit late administr ventricular function mortal 